News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Culture: Rare Hundertwasser Conservation Posters Found After 40 Years

When Jan and Arnold Heine put a roll of conservation posters into storage in 1974 they had no idea that 42 years later they would be collectors items. More>>

Scoop Review Of Books: The Stolen Island: Searching for ‘Ata by Scott Hamilton

Reviewed by Michael Horowitz
Located even further south than temperate Noumea, Tonga’s tiny island of ‘Ata might have become the jewel of the kingdom’s burgeoning tourist industry. Imagine a Tongan resort that would not only be mild in winter, but pleasant in summer. More>>

Reviewed by Michael Horowitz
Located even further south than temperate Noumea, Tonga’s tiny island of ‘Ata might have become the jewel of the kingdom’s burgeoning tourist industry. Imagine a Tongan resort that would not only be mild in winter, but pleasant in summer. More>>

Scoop Review Of Books: No Pretence. No Bullshit. Fine Poem.

John Dickson doesn’t publish much; never has. Indeed, this new collection is his first such in 18 years. As he wryly and dryly states,

I’ve published two slim volumes, and spent all
My time working on the next.
(from Wasp p.67) More>>

Scoop Review of Books: Extraordinary Anywhere: Essays On Place From Aotearoa NZ

The New Zealand landscape undoubtedly is very beautiful, but so is the British one, and my attachment to this country is much more about some particular places, and the memories and emotions that in them combine, than it is about the landscape as a whole. More>>

Canonisation Fodder: Suzanne Aubert Declared ‘Venerable’

Suzanne Aubert, the founder of the Sisters of Compassion New Zealand’s home grown order of Sisters, has been declared ‘venerable’, a major milestone on the path to sainthood in the Catholic Church. More>>

“I Have Not Performed Well Enough”: Ernie Merrick Leaving Wellington Phoenix

Ernie Merrick has stepped down from his position as Wellington Phoenix FC Head Coach. The club would like to thank Ernie for his contribution to Wellington Phoenix and wish him all the best in his future endeavours. More>>

Ray Columbus: NZ Music Icon Passes Away

60s New Zealand music Icon Ray Columbus has passed away peacefully at his home north of Auckland... Ray Columbus enjoyed more than three decades at the top of NZ entertainment as a singer, songwriter, bandleader, music manager and TV star. More>>

Review: Bernard Herrmann's Scores For 'Vertigo' & 'Psycho'

Howard Davis: The NZSO's adventurousness was richly-rewarded, as the deeply appreciative Wellington audience was given the opportunity not only to see a couple of Alfred Hitchcock's greatest films, but also to hear fine renditions of two of Bernard Herrmann's most accomplished film scores. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news